Prevention of vasospasm in subarachnoid hemorrhage


Phase N/A Results

Trial Description

To determine if the use of nimodipine reduces the severity of ischemic deficits secondary to vasospasm.


  • Nimodipine (NimotopĀ®)Drug
    Other Names: The treatment group
    Intervention Desc: Calcium channel blocker (L-type calcium channels)

Trial Design

Prospective, randomized, double blind, placebo-controlled trial of 70 patients.

Patient Involvement

Patients were randomized to receive nimodipine orally (60 mg every four hours) or placebo for 21 days. Tranexamic acid (6 g/day) was also administered to most patients.


Type Measure Time Frame Safety Issue
Primary Glasgow Outcome Scale score at the end of treatment.